INTRODUCTION
Dialysis-related amyloidosis (DRA) is a serious complication of chronic renal failure and has been recognized for over a decade. However, its pathogenesis is still not fully understood. It is indisputable that β 2 -microglobulin (β 2 -M) is the major constituent protein of DRA. Despite the finding of monocytes/macrophages around amyloid fibrils in histologic studies, the factor that stimulates their infiltration has yet to be elucidated. The acidic isoform of β 2 -M and the chemical modification by advanced glycation end products (AGEs) have been implicated in DRA arthropathies that may result from heightened cellular inflammatory responses secondary to progressive accumulation of AGEs in chronic amyloid deposits. Herein, we revisit this important complication of dialysis and provide an update on recent advances.
CLINICAL FEATURES
Systemic β 2 -M amyloidosis is generally believed to appear some time after the commencement of dialysis, notably 5-7 years, and its prevalence increases with the duration of dialysis. In one study, β 2 -M-amyloid deposits occurred in 31% of patients after a median of only 27 months of continuous ambulatory peritoneal dialysis (CAPD), suggesting that β 2 -M amyloidosis may occur much earlier than previously thought (1). In another study, the prevalence increased from 21% within the first 2 years to 100% after 13 years of dialysis (2) . The prevalence did not differ significantly between patients on peritoneal dialysis and hemodialysis (HD), at 31% and 50% in CAPD and HD, respectively (1) .
The most common clinical manifestations include the occurrence of carpal tunnel syndrome (CTS) and periarticular cystic bone lesions in combination with destructive arthropathy. Osteoarticular sites, particularly the synovial membrane, were commonly the targets of β 2 -M-amyloid deposition. In addition, β 2 -M-amyloid may play a role in the pathogenesis of spondyloarthropathy, in which the deposits have been found in intervertebral discs, apophysial joints and ligaments. The clinical manifestations may range from being asymptomatic to radiculopathy, stiffness, mechanical strain and medullary compression leading to paraplegia or the cauda equina syndrome (3, 4) . Deposition of β 2 -M-amyloid in tissues other than the musculoskeletal system tends to occur at a later stage and rarely causes major sequelae. These include intestinal and myocardial involvement (5). β 2 -M-amyloid renal calculi have also been reported in patients on dialysis (6) .
Carpal tunnel syndrome
Patients usually present with bilateral hypesthesia, hypalgesia, hand pain at night or during dialysis, thenar wasting and weakness. In severe cases, patients may develop the typical "amyloid hand" with hand contracture and atrophy of digital muscles. Deposition of β 2 -M-amyloid is usually found adjacent to collagen in carpal synovia, flexor tendon sheaths, transverse carpal ligament and perineural tissue (7) . In "amyloid hand", the deposition involves tendons and tendon sheaths of the palm and fingers (8) . Nerve conduction of the median nerve is impaired. The incidence of CTS increases with time on dialysis, starting at about 5 years of treatment, and rising to 50% at 15 years and 100% after 20 years of dialysis with cuprophane membranes (7) .
Destructive arthropathy
Destructive arthropathy predominantly affects large and medium-sized joints. The most commonly affected are the sternoclavicular joints, followed by the knee joints, and the shoulder joints (2), characterized by arthralgia, joint stiffness, effusion and swelling of capsules and adjacent tendons (9) . Additionally, peri-articular bone cysts, commonly affecting large bones and bones around synovial joints, contain β 2 -M-amyloid deposits, and increase in number and size with time on dialysis and do not regress after renal transplantation (10) . Destructive arthropathy may also cause pathological fractures over weight-bearing joints especially the femoral neck (11) . and immunohistochemical demonstration of β 2 -M within deposits (13, 14) . Electron microscopy demonstrates parallel bundles of 8-10 nm curvilinear fibrils which show intense immunoreaction to anti-β 2 -M antisera (13) . Diagnostic biopsy material usually has to be obtained from synovial membranes or bone lesions. Contrary to the other non-amyloid induced arthritis, the synovial fluid of DRA joint effusion is serous, sterile and non-inflammatory.
Serum levels of β 2 -M do not help in diagnosis, as elevation of serum β 2 -M is a universal characteristic of chronic renal failure, and the absolute serum level does not correlate with clinical or radiologic evidence of β 2 -M amyloidosis (15) (16) (17) (18) . Although serum levels are increased by more than 40-fold in patients with renal failure (15), the incidence of β 2 -M amyloidosis appears to be more related to the duration on dialysis treatment than the serum level. Indeed, serum level may even decline in patients treated with longer duration of HD (19) .
The peri-articular cystic lesions are radiolucent. An important differential diagnosis is the brown tumor of secondary hyperparathyroidism. Other radiological findings include destructive joint changes ranging from erosions and marginal defects, particularly at synovial insertion sites. Narrowing of the intervertebral disc space with destructive changes may be seen in patients with spondyloarthopathy. Other imaging modalities that have been used to search for evidence of β 2 -M amyloidosis include computed tomography (20) and magnetic resonance imaging (21) , but these techniques have low diagnostic specificity. Ultrasonography could be used to monitor the deposition of β 2 -M-amyloid non-invasively. Thickening of the joint capsules, biceps tendons and the rotator cuffs and echogenic structures between muscle groups have also been measured (22, 23) .
Scintigraphic methods with 123 Iodine-labelled serum amyloid P component or with 131 Iodine-labelled β 2 -M yield more specific information. As circulating β 2 -M protein incorporates into growing β 2 -M-amyloid fibrils (24, 25) , scanning with 131 Iodine-labelled β 2 -M yielded tracer pattern that corresponded well with the clinical distribution of β 2 -M amyloidosis (26) . One advantage of this method is that the sensitivity exceeds that of combined clinical and radiological investigations (27) . Further innovation has improved the specificity of scintigraphy by using recombinant human β 2 -M together with 111 Indium labelling. This method provides a homogenous and safe recombinant protein source and offers higher detection sensitivity (28) .
PATHOGENESIS
The amyloidogenic mechanism of β 2 -M protein has not been clearly delineated. β 2 -M is an 11.8 kD protein and serum levels are increased by 40-60 fold in patients with renal failure. The normal serum level of β 2 -M is 0.5 mg to 2.0 mg/L, which may be increased in inflammatory states. One possible consequence of such elevated levels of β 2 -M is the continuous incorporation of the circulating precursor protein into growing β 2 -M-amyloid fibrils (29) . However, it is unlikely that the passive presence of intact β 2 -M per se contributes to amyloidogenesis, because no difference in the plasma levels of intact β 2 -M has been found between HD patients with and without this complication (15) . Therefore, several modifications of β 2 -M have been suggested to induce its amyloidogenic capacity (30, 31) .
Miyata et al demonstrated chemical modification of β 2 -M in amyloid fibrils with AGEs (32). Different AGE products have been found in amyloid fibrils (33, 34) . The AGEmodified proteins are chemotactic for monocytes and stimulate macrophages to secrete the inflammatory cytokines TNF-α, IL-6 and IL-1β (35) . Other studies have also shown that AGE-modified β 2 -M induced the secretion of TNF-α and IL-1β from macrophages to stimulate collagenase synthesis in cultured synovial cells (35) , which may contribute to progressive bone loss and the formation of bone cysts. Monocyte chemotaxis and TNF-α production induced by AGE-modified β 2 -M can be inhibited by blockade of the receptor for AGEs (RAGE), suggesting that the biologic effects of AGE-β 2 -M on monocytes/ macrophages are mediated via RAGE (36) . In addition to directly stimulating proinflammatory cytokine release from monocyte/macrophages, AGE-β 2 -M may recruit inflammatory cells through regulation of synoviocytederived chemokines. Hou et al (37) recently described the expression of RAGE on the surface of synovial fibroblasts which are upregulated in patients with DRA. The interaction between AGE-β 2 -M and RAGE on human synovial fibroblasts superinduced the expression of MCP-1. These findings suggest that RAGE-mediated pertubation of synoviocyte function might contribute to the pathogenesis of the cellular immune response associated with DRA. Other studies that suggest an active role of β 2 -M in bone resorption include the induction of net calcium efflux from neonatal mouse calvariae leading to bone dissolution (38) and the observation of bone resorption following direct β 2 -M injection into neonatal mice (39) .
Morphologically, Garbar et al found that the thickness of amyloid deposits correlated with the dialysis duration and categorized β 2 -M depositions into three stages (40) . Firstly, β 2 -M protein precipitates on the surface of cartilage as a thin layer without infiltration by macrophage (41) . This was usually associated with small deposits (median 0.03 mm 2 ) and occurred after a mean duration of 39 months. In the second stage, β 2 -M expanded to the synovia and joint capsules and the deposits were thicker (median 0.19 mm 
TREATMENT AND PREVENTION
To date, there is no specific treatment for β 2 -M amyloidosis. An important preventive strategy is to remove β 2 -M from the plasma efficiently. Conventional dialysis membranes using cuprophane and cellulose acetate are impermeable to β 2 -M, and may even promote amyloidosis by altering the conformational structure of β 2 -M. On the other hand, it is possible to reduce plasma β 2 -M levels to some extent by using high-flux, biocompatible polyacrylonitrile or polysulfone membranes, which can eliminate larger molecular weight solutes. These noncellulosic membranes act by adsorption of β 2 -M, and to a lesser extent, by convective removal that is dependent on high rates of ultrafiltration. Chanard et al (44) demonstrated that routine use of polyacrylonitrile membranes could reduce the amount of circulating β 2 -M and lower the incidence of CTS. In addition, Koda et al showed that switching from conventional-membrane to high flux-membrane hemodialysis reduced the risk of CTS and overall mortality (45) . Despite these promising observations, DRA is inadequately corrected by high-flux dialysis. This is because (i) high-flux membranes have poor β 2 -M clearing efficiency, and (ii) β 2 -M adsorption is usually complete early in the dialysis procedure. The efficiency of high-flux membranes is further compromised by dialyzer reuse (46) . These drawbacks have prompted researchers to explore alternative means of improving β 2 -M clearance. Ronco et al (47) pioneered the use of a new hemoperfusion adsorbent device designed specifically to adsorb β 2 -M by virtue of a polymer coating, and reported substantial reduction of β 2 -M levels in two patients. The extracorporeal device is made of polysulfone and contained 300 g hydrated polystyrene resin beads coated with polyvinylpyrollidone. More recently, Suzuki et al (48) described alleviation of joint pain with Lixelle, a direct hemoperfusion-type adsorbent column developed for selective elimination of β 2 -M. Further investigation is required to validate the safety, and clinical efficacy, as well as simplify the complexity of this coupled hemoperfusionhemodialysis technique.
Another therapeutic option is nocturnal hemodialysis. Using a smaller polysulfone dialyzer (F40, surface area of 0.7 m 2 ) with lower blood and dialysate flow rates for 8 h, six nights a week, Raj et al (49) demonstrated that nocturnal hemodialysis provided a much higher clearance of β 2 -M than conventional, thrice weekly hemodialysis, and effectively lowered pre-dialysis plasma β 2 -M concentration. In places where the practice of nocturnal hemodialysis is not feasible, hemodiafiltration (HDF), a method combining the convective component of hemofiltration and the diffusive capacity of high-flux hemodialysis, offers an improved solute clearance both for low and high molecular weight uremic toxins, and has an increased dialysis efficiency compared to high-flux dialysis (50, 51) . It should be noted that neither nocturnal dialysis nor hemodiafiltration could normalize the grossly elevated plasma levels of the microglobulin. Whether the decrease in timeaveraged concentration of β 2 -M in either nocturnal hemodialysis or HDF may postpone or even prevent DRA requires further clinical correlation. Finally, kidney transplantation is by far the most definitive form of treating and preventing DRA. A functional allograft halts disease progression and leads to rapid relief of osteoarticular symptoms although regression of amyloid deposits probably does not occur (10) .
